SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : XOMA. Bull or Bear?
XOMA 29.95+10.0%Jan 8 3:59 PM EST
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Cacaito who wrote (10502)6/21/1999 10:08:00 AM
From: aknahow  Read Replies (1) of 17367
 
The P II Trauma trial dosage for the first 400 was 4 mg per Kg of weight for 2
days. In the continued phase of P II I believe they tried some different dosage regimes.
One I have seen for Jan of 98 mentioned 3 days.

My question is do we know what dosage is being used and for how many days in the P
III trial. Admit I don't know what mental use I will make out of this information but I
would like to know nonetheless. From a lay persons view even understand that at times
less is more, in general it is had knot to believe that more and longer is better.

Will probably ask Martin, if there is no answer already available. The ISS scores for
the treatment arm were a lot lower than for the placebo arm so it is not that clear how
significant the positive results were.

Why not a continuous infusion? Why just two days? Is the threat of infection and
endotoxin over in two days? Is it not cost effective to do more? Will certain conditions
be treated differently? Just searching for questions that make sense and will shed some
light on benefit to the patient, and market for the product. Obviously for chronic
conditions XOMA is already looking for ways to provide the drug on a continuos basis.
Perhaps an acute condition is taken care of in two days, three days and thats that. ????
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2026 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News